All In Biotech

Drug Trial Radar · NCT05376423

To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence

A Randomized, Open-Label, Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence

Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 2, 2022

Primary completion

Dec 2024

Study completion Jun 2025

Sponsor

Lead sponsor
National Taiwan University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence

Conditions

  • Esophageal Cancer

Interventions

  • OBI-833/OBI-821Biological

    OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survival rateTime frame: one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.